TY - JOUR
T1 - Paediatric extracranial germ-cell tumours
AU - Shaikh, Furqan
AU - Murray, Matthew J.
AU - Amatruda, James F.
AU - Coleman, Nicholas
AU - Nicholson, James C.
AU - Hale, Juliet P.
AU - Pashankar, Farzana
AU - Stoneham, Sara J.
AU - Poynter, Jenny N.
AU - Olson, Thomas A.
AU - Billmire, Deborah F.
AU - Stark, Daniel
AU - Rodriguez-Galindo, Carlos
AU - Frazier, A. Lindsay
N1 - Funding Information:
DS received grants from the Teenage Cancer Trust during the conduct of the study. ALF has served on the Germ Cell Tumor Advisory Board for Seattle Genetics and has consulted for Decibel Therapeutics. All other authors declare no competing interests.
Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Management of paediatric extracranial germ-cell tumours carries a unique set of challenges. Germ-cell tumours are a heterogeneous group of neoplasms that present across a wide age range and vary in site, histology, and clinical behaviour. Patients with germ-cell tumours are managed by a diverse array of specialists. Thus, staging, risk stratification, and treatment approaches for germ-cell tumours have evolved disparately along several trajectories. Paediatric germ-cell tumours differ from the adolescent and adult disease in many ways, leading to complexities in applying age-appropriate, evidence-based care. Suboptimal outcomes remain for several groups of patients, including adolescents, and patients with extragonadal tumours, high tumour markers at diagnosis, or platinum-resistant disease. Survivors have significant long-term toxicities. The challenge moving forward will be to translate new insights from molecular studies and collaborative clinical data into improved patient outcomes. Future trials will be characterised by improved risk-stratification systems, biomarkers for response and toxic effects, rational reduction of therapy for low-risk patients and novel approaches for poor-risk patients, and improved international collaboration across paediatric and adult cooperative research groups.
AB - Management of paediatric extracranial germ-cell tumours carries a unique set of challenges. Germ-cell tumours are a heterogeneous group of neoplasms that present across a wide age range and vary in site, histology, and clinical behaviour. Patients with germ-cell tumours are managed by a diverse array of specialists. Thus, staging, risk stratification, and treatment approaches for germ-cell tumours have evolved disparately along several trajectories. Paediatric germ-cell tumours differ from the adolescent and adult disease in many ways, leading to complexities in applying age-appropriate, evidence-based care. Suboptimal outcomes remain for several groups of patients, including adolescents, and patients with extragonadal tumours, high tumour markers at diagnosis, or platinum-resistant disease. Survivors have significant long-term toxicities. The challenge moving forward will be to translate new insights from molecular studies and collaborative clinical data into improved patient outcomes. Future trials will be characterised by improved risk-stratification systems, biomarkers for response and toxic effects, rational reduction of therapy for low-risk patients and novel approaches for poor-risk patients, and improved international collaboration across paediatric and adult cooperative research groups.
UR - http://www.scopus.com/inward/record.url?scp=84977556590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84977556590&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(15)00545-8
DO - 10.1016/S1470-2045(15)00545-8
M3 - Review article
C2 - 27300675
AN - SCOPUS:84977556590
SN - 1470-2045
VL - 17
SP - e149-e162
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 4
ER -